P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson,Jean-Baptiste Mear,Charles Herbaux,Jean-Marc Schiano,Olivier Casasnovas,Aspasia Stamatoullas,Bénédicte Deau,Anna Schmitt,Georges Garnier,Caroline Regny,Krimo Bouabdallah,Marie-Pierre Moles-Moreau,Hervé Ghesquières,Adrian Tempescul,Remy Dulery,Emmanuelle Nicolas-Virelizier,Alain Delmer,Cécile Borel,Adrien Chauchet,Diane Damotte,Laurent Dercle,Pauline Brice,Roch Houot,Lysa +23 more
TL;DR: Most patients with R/R HL treated with anti-PD1 monotherapy eventually progressed, notably those who did not achieve a CR, and this information should be considered when evaluating the risk/benefit ratio of allo-HSCT after anti- PD1 therapy.
Journal ArticleDOI
Bone marrow histological patterns can predict survival of patients with grade 1 or 2 follicular lymphoma: a study from the Groupe d'Etude des Lymphomes Folliculaires.
Danielle Canioni,Pauline Brice,Eric Lepage,Myrna Chababi,Véronique Meignin,Bruno Salles,Luc Xerri,Pierre-Yves Peaud,Philippe Rousselot,Michel Peuchmaur,Philippe Solal-Celigny,Nicole Brousse +11 more
TL;DR: Results indicate that BMB histology can predict survival of FL patients with a high tumour burden, and may help in defining their treatment.
Journal ArticleDOI
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
Barbara Pro,R. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Rod Ramchandren,Michelle A. Fanale,Jean M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Brentuximab vedotin induced objective responses in 86% of pts with highly refractory sALCL, including a high proportion of CRs, with manageable AEs, and responded to treatment-related adverse events of any grade at the meeting.
Journal ArticleDOI
Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma
Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Dirk Huebner,Dana A. Kennedy,Andrei R. Shustov +12 more
TL;DR: A heavily pre-treated pt population with poor prognosis, 62% had primary refractory disease, 26% had failed a prior autologous stem cell transplant (SCT), and 72% had ALK-negative disease.
Journal ArticleDOI
Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients.
Mathilde Lamarque,Céline Bossard,Adrien Contejean,Pauline Brice,Marie Parrens,Steven Le Gouill,Josette Brière,Reda Bouabdallah,Danielle Canioni,Hervé Tilly,Brigitte Bouchindhomme,Emmanuel Bachy,Richard Delarue,Corinne Haioun,Philippe Gaulard +14 more
TL;DR: Brentuximab vedotin is an antibody-drug-conjugate directed against CD30 antigen, recently approved for the treatment of relapsed anaplastic large-cell lymphomas and it has been suggested that a significant proportion of peripheral T- cell lymphomas (PTCL) may be potential.